Tatyana Vlaykova

Prof. Dr. Tatyana Vlaykova

Medical University Plovdiv, Plovdiv, Bulgaria
+1
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2009 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
MGMaya Gulubova
Maya Gulubova
Tatyana VlaykovaTatyana Vlaykova
Tatyana Vlaykova

29 December 2001 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
JNJohanna Nikkola
Johanna Nikkola
PPPia Pia
Pia Pia
Tatyana VlaykovaTatyana Vlaykova
Tatyana Vlaykova
MHMarjo Hahka‐Kemppinen
Marjo Hahka‐Kemppinen
Veli-Matti KähäriVeli-Matti Kähäri
Veli-Matti Kähäri
SPSeppo Pyrhönen
Seppo Pyrhönen

9 November 2011 in International Journal of Colorectal Disease
Verified
Journal Article
Closed access
PDF file
MGMaya V. Gulubova
Maya V. Gulubova
JAJulian R. Ananiev
Julian R. Ananiev
Tatyana VlaykovaTatyana Vlaykova
Tatyana Vlaykova
YYYovcho Yovchev
Yovcho Yovchev
VTVanya Tsoneva
Vanya Tsoneva
IMIrena M. Manolova
Irena M. Manolova

14 June 2000 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
ISIlari Sauroja
Ilari Sauroja
JSJohanna Smeds
Johanna Smeds
Tatyana VlaykovaTatyana Vlaykova
Tatyana Vlaykova
Rajiv KumarRajiv Kumar
Rajiv Kumar
LTLauri Talve
Lauri Talve
SPSeppo Pyrhönen
Seppo Pyrhönen

1 May 2015 in Journal of Biotechnology
Verified
Journal Article
Open access
HKHilal S. Khalil
Hilal S. Khalil
VMVanio Mitev
Vanio Mitev
Tatyana VlaykovaTatyana Vlaykova
Tatyana Vlaykova
LCLaura Cavicchi
Laura Cavicchi
NZNikolai Zhelev
Nikolai Zhelev
Seliciclib (R-Roscovitine) was identified as an inhibitor of CDKs and has undergone drug development and clinical testing as an anticancer agent. In this review, the authors describe the discovery of Seliciclib and give a brief summary of the biology of the CDKs Seliciclib inhibits. An overview of the published in vitro and in vivo work supporting the development as an anti-cancer agent, from in vitro experiments to animal model studies ending with a summary of the clinical trial results and trials underway is presented. In addition some potential non-oncology applications are explored and the potential mode of action of Seliciclib in these areas is described. Finally the authors argue that optimisation of the therapeutic effects of kinase inhibitors such as Seliciclib could be enhanced using a systems biology approach involving mathematical modelling of the molecular pathways regulating cell growth and division.

1 February 2004 in Melanoma Research
Verified
Journal Article
Closed access
JNJohanna Nikkola
Johanna Nikkola
PPPia Pia
Pia Pia
Tatyana VlaykovaTatyana Vlaykova
Tatyana Vlaykova
MHMarjo Hahka-Kemppinen
Marjo Hahka-Kemppinen
JHJyrki Heino
Jyrki Heino
SPSeppo Pyrhönen
Seppo Pyrhönen
The expression pattern of integrin-type cell adhesion receptors is often changed during malignant transformation. In the present work, we studied the prognostic significance of beta1 and alphav integrin chains for survival of patients with metastatic melanoma. The expression levels of beta1 integrin were also compared with those of Bcl-2, an anti-apoptotic protein, the presence of which is associated with treatment response and survival in melanoma. The expression of beta1 and alphav integrins in 68 melanoma metastases obtained from 55 patients treated with combined chemoimmunotherapy was studied by immunohistochemistry using anti-beta1 and anti-alphav antibodies. The patients were divided into two groups (using a cut-off point of >/= 81%) for beta1 integrin expression levels and into three categories (negative/low, median, high) for alphav integrin expression levels. All tumours were positive for beta1 integrin, and the tumours (n = 6) which had the highest alphav score were also strongly positive for beta1 (94%; P = 0.0055). Patients (n = 43) with 80% or less beta1 integrin-positive tumour cells in their samples had a median disease-free survival (DFS) of 17.0 months, and patients (n = 12) with 81% or more beta1 integrin-positive tumour cells had a DFS of only 5.7 months (P = 0.0001). Patients (n = 32) with low alphav integrin expression levels had shorter DFS (median 12.3 months; P = 0.0146) than patients (n = 20) with median expression levels (median 16.7 months; P = 0.0146). However, three patients who had a very strong alphav expression in their tumours had a median DFS of only 1.8 months (P = 0.0146). Median level expression of beta1 integrin was associated with the presence of Bcl-2 in tumour cells (P = 0.0033). Our results suggest that beta1 and alphav integrin chains are independently expressed in metastatic melanoma and may have an effect on the metastatic potential of melanoma cells.